Ovarian carcinosarcomas: Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum

Basit Öğe Kaydı
dc.authoridAYDIN, YUCEL/0000-0001-6727-6296
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridEralp, Yesim/0000-0001-9603-4755
dc.authoridOzluk, Yasemin/0000-0002-7191-0488
dc.authorwosidTopuz, Samet/AAY-8615-2020
dc.authorwosidAYDIN, YUCEL/AAA-8522-2019
dc.authorwosidSaip, pınar/AAT-1500-2020
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidEralp, Yesim/AAD-7194-2020
dc.authorwosidOzluk, Yasemin/L-1814-2018
dc.contributor.authorCicin, Irfan
dc.contributor.authorSaip, Pinar
dc.contributor.authorEralp, Yesirn
dc.contributor.authorSelam, Meltern
dc.contributor.authorTopuz, Samet
dc.contributor.authorOzluk, Yasernin
dc.contributor.authorAydin, Yucel
dc.date.accessioned2024-06-12T11:11:51Z
dc.date.available2024-06-12T11:11:51Z
dc.date.issued2008
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective. To evaluate the clinicopathological prognostic factors and outcome of chemotherapy in ovarian carcinosarcomas. Methods. We reviewed the records of 26 patients treated from 1990 to 2006 at the Oncology Institute of Istanbul University. Clinical data including demographics, stage, surgery, chemotherapy, and survival were collected from patients' charts. Results. All patients underwent initial debulking surgery. Optimal debulking was achieved in 21 (81%) patients. The most striking clinicopathological finding was the high incidence of hemorrhagic ascites (n: 6) which was observed in 60% of the patients with ascites (n: 10). The overall median survival of the patients was 26 months. Residual disease was associated with a decreased overall survival, P=0.04. Median survival (50 months vs 9.7 months, P=0.042) of the patients with early stage disease were longer than the patients with advanced stage. Twenty-two patients received platinum-based combination chemotherapy. There was a trend for increased median survival in the patients who were treated with carboplatin/paclitaxel combination (P=0.066). Although the numbers were insufficient for statistical evaluation, the patients treated with ifosfamide combinations had improved survival (36 months vs 26 months). However, when the patients treated with ifosfamide and carboplatin/ paclitaxel combinations were combined, survival was statistically improved compared to the other regimens (36 months vs 9.7 months, P=0.04). Chemotherapy regimens containing doxorubicin or cyclophosphamide were not encouraging. Stage (P=0.02) and adjuvant platinum-based chemotherapy containing either paclitaxel or ifosfamide (P=0.024) remained predictive of outcome in the multivariate analysis. Conclusions. Hemorrhagic ascites can be used in the initial differential diagnosis of ovarian carcinosarcomas. Stage, optimal debulking and type of adjuvant therapy were statistically significant prognostic predictors of ovarian carcinosarcomas. We advise that patients with ovarian carcinosarcomas should be treated by optimal cytoreduction followed by adjuvant platinum/taxan or platinum/ifosfamide combinations. C 2007 Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.ygyno.2007.09.003
dc.identifier.endpage140en_US
dc.identifier.issn0090-8258
dc.identifier.issue1en_US
dc.identifier.pmid17936342en_US
dc.identifier.scopus2-s2.0-37349019710en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage136en_US
dc.identifier.urihttps://doi.org/10.1016/j.ygyno.2007.09.003
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22958
dc.identifier.volume108en_US
dc.identifier.wosWOS:000252605200025en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAcademic Press Inc Elsevier Scienceen_US
dc.relation.ispartofGynecologic Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOvarian Carcinosarcomaen_US
dc.subjectChemotherapyen_US
dc.subjectHemorrhagic Ascitesen_US
dc.subjectDebulking Surgeryen_US
dc.subjectMixed Mesodermal Tumorsen_US
dc.subjectGynecologic-Oncology-Groupen_US
dc.subjectMullerian Tumorsen_US
dc.subjectSurgical Cytoreductionen_US
dc.subjectIfosfamideen_US
dc.subjectExperienceen_US
dc.subjectCisplatinen_US
dc.subjectFeaturesen_US
dc.subjectSarcomaen_US
dc.subjectMesnaen_US
dc.titleOvarian carcinosarcomas: Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinumen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu